Top Page
Vivesto AB
(VIVE)
Vivesto AB (VIVE) vs. iShares MSCI Sweden ETF (EWD)
Vivesto AB Business Overview & Revenue Model
Vivesto AB Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2022 | Dec 2021 | Apr 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 1.01M | 26.19M | 201.84M |
| Gross Profit | 0.00 | -3.19M | -10.66M | -17.93M | 215.84M |
| EBITDA | -34.38M | -36.56M | -89.76M | -97.62M | -11.50M |
| Net Income | -34.08M | -39.75M | -367.03M | -138.94M | -10.53M |
Balance Sheet | |||||
| Total Assets | 149.04M | 172.88M | 355.88M | 594.31M | 863.54M |
| Cash, Cash Equivalents and Short-Term Investments | 2.10M | 32.29M | 142.51M | 97.27M | 287.40M |
| Total Debt | 13.00M | 0.00 | 8.17M | 10.43M | 0.00 |
| Total Liabilities | 24.46M | 14.55M | 30.45M | 44.59M | 176.80M |
| Stockholders Equity | 124.58M | 158.33M | 325.42M | 549.71M | -1.22B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -47.25M | -80.79M | -179.91M | -211.41M |
| Operating Cash Flow | -33.96M | -47.25M | -80.52M | -145.56M | -204.86M |
| Investing Cash Flow | 21.85M | 43.40M | -45.28M | 118.65M | -21.55M |
| Financing Cash Flow | 13.00M | 0.00 | 128.76M | -5.81M | -6.01M |
Vivesto AB Peers Comparison
Vivesto AB Corporate Events
Vivesto AB, a Swedish oncology-focused development company listed on Nasdaq Stockholm, is advancing drug candidates for difficult-to-treat cancers in both human and veterinary medicine, including its blood cancer project Cantrixil and the Paccal Vet program for companion animals. The group is targeting areas where there is both major medical need and significant commercial opportunity.
The company has completed a rights issue of shares and a directed set-off share issue to certain guarantors, substantially increasing its share capital base. Following these transactions, Vivesto’s total number of shares and votes has risen to 1,107,136,910, a change that reshapes the firm’s ownership structure and may influence future capital market dynamics for existing and new shareholders.
Vivesto AB’s board has approved a directed issue of 31,050,000 new shares to guarantors of its recently completed rights issue, using the mandate granted at an extraordinary general meeting in December 2025. The compensation shares, priced at SEK 0.10 each and paid via set-off of guarantee commission claims, mainly reward existing shareholder Arwidsro Investment AB and certain other guarantors who opted for share-based compensation, while remaining guarantors will receive about SEK 2.6 million in cash. By settling most guarantee fees in shares rather than cash, Vivesto preserves liquidity and strengthens working capital, albeit at the cost of approximately 2.8 percent dilution for existing shareholders, with the total number of shares rising to 1,107,136,910; the board, advised by Bergs Securities, considers the terms market-based, underlining the company’s efforts to shore up its capital structure as it advances its oncology pipeline.
Vivesto AB has completed a fully subscribed rights issue, raising approximately SEK 53.8 million before costs at a subscription price of SEK 0.10 per share, with about 62.1 percent of the offering taken up through subscription rights, 1.9 percent without rights, and the remaining 36.0 percent covered by guarantee undertakings from existing shareholders and external investors, including a significant contribution from major shareholder Arwidsro Investment AB. The capital increase doubles the company’s share count to 1,076,086,910 shares, implying a 50 percent dilution for non-participating shareholders, with a potential additional 5.4 percent dilution from a planned compensation issue to guarantors, while trading in the newly issued shares on Nasdaq Stockholm is expected around mid-February 2026, strengthening Vivesto’s balance sheet and providing funding capacity albeit at the cost of substantial dilution.
Vivesto AB has published an information document for a fully covered rights issue of approximately SEK 53.8 million, offering existing shareholders one new share at SEK 0.10 for each share held, with trading in subscription rights on Nasdaq Stockholm from 8–19 January 2026 and a subscription period running to 22 January 2026. The capital raise, backed by subscription commitments and guarantee undertakings from major shareholders and external investors, is intended to fund ongoing Paccal Vet pilot and dose-determination studies in dogs and cats, preclinical and pilot studies for Cantrixil, partial repayment of loans to Arwidsro, and general corporate purposes, with the company assessing that the proceeds will finance operations into the second half of 2027.
Vivesto AB’s extraordinary general meeting on 22 December 2025 approved a major rights issue of up to 538,043,455 new shares at SEK 0.10 per share, with preferential subscription rights for existing shareholders, requiring amendments to the company’s articles of association to expand the limits for share capital and number of shares. Shareholders also backed a top guarantee arrangement under which Arwidsro Investment AB will guarantee up to SEK 15 million of any unsubscribed portion of the rights issue and authorised the board to issue additional shares as guarantee commission to underwriters, moves that collectively aim to secure Vivesto’s funding base and strengthen its financial position as it advances its oncology pipeline.
Vivesto AB has engaged Liberi Group, a global life science consultancy, to help identify international partners for its Paccal Vet and Cantrixil programs. This collaboration aims to accelerate the development and commercialization of these drug candidates by leveraging Liberi Group’s expertise in securing high-quality partners. The partnership is expected to enhance Vivesto’s ability to achieve upcoming milestones and strengthen its market position in both veterinary and human oncology sectors.